Navigation Links
Par Pharmaceutical Reports Fourth Quarter and Full Year 2007 Results
Date:2/29/2008

WOODCLIFF LAKE, N.J., Feb. 29 /PRNewswire-FirstCall/ -- Par Pharmaceutical Companies, Inc. (NYSE: PRX) today reported fourth quarter and full year 2007 results ended December 31, 2007.

Fourth Quarter and 2007 Results

For the fourth quarter ended December 31, 2007, Par reported total revenues of $155.1 million and income from continuing operations of $5.5 million, or $0.16 per diluted share. This is compared with reported revenues of $183.6 million and income from continuing operations of $5.0 million, or $0.15 per diluted share, for the same period in 2006. For the year ended December 31, 2007, Par reported total revenues of $769.7 million and income from continuing operations of $51.1 million, or $1.47 per diluted share. This is compared with reported revenues of $725.2 million and income from continuing operations of $6.7 million, or $0.19 per diluted share, for 2006.

Fourth quarter 2007 reported, or GAAP, income from continuing operations included a pre-tax gain of $3.1 million from the Company's sale of its remaining investment in Optimer Pharmaceutical, Inc. ("Optimer") common stock and $4.6 million of additional share-based compensation expense related to the Company's issued stock option tender offer. Adjusting for these items, income from continuing operations for the fourth quarter of 2007 was $6.5 million, or $0.19 per diluted share. By comparison, income from continuing operations for fourth quarter 2006 included a $3.2 million investment gain, tempered by severance costs of $5.2 million, and a $1.0 million asset impairment. Adjusting for these items, income from continuing operations for the fourth quarter of 2006 was $6.9 million, or $0.20 per diluted share.

Par's reported, or GAAP, income from cont
'/>"/>

SOURCE Par Pharmaceutical Companies, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine news :

1. Nastech Pharmaceutical Company Inc. to Hold Conference Call to Discuss Corporate Restructuring and Future Strategy on Monday, March 3, 2008
2. China Sky One Medical, Inc. to Acquire Heilongjiang Tianlong Pharmaceutical, Inc.
3. MAP Pharmaceuticals Reports 2007 Fourth Quarter and Year End Financial Results
4. KV Pharmaceutical Reports Record Revenues for Fiscal 2008 Third Quarter and Year-to-Date on a Preliminary Basis
5. Acura Pharmaceuticals, Inc. Announces Andrew Reddick, President & CEO, To Take Medical Leave and Appointment of Richard Markham as Chairman of the Board
6. Idenix Pharmaceuticals to Present at the SIGnificant Investment Options in Healthcare Conference
7. VIA Pharmaceuticals to Present at Susquehanna and Rodman & Renshaw Conferences on March 4, 2008
8. Lotus Pharmaceuticals Raises $5 Million in Private Placement
9. Galderma Reaches Agreement to Acquire CollaGenex Pharmaceuticals
10. Transcept Pharmaceuticals to Present at the Susquehanna Financial Groups SIGnificant Investment Options in Healthcare Conference
11. Onyx Pharmaceuticals Reports Fourth Quarter and Twelve-Month 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/3/2009)...INGTON, July 3 Republic...r language in health care reform legislation that ... this happens, many women could lose coverage for ...rently includes. Plus, millions of uninsured women...te having been promised a better quality of life. ...
(Date:7/3/2009)... Eva,s Village, ( http://www.Evas...ty Charity, Seeks Buyers for 35mm Michael Jackson ... Paterson, NJ (PRWEB) July....org ), a non-profit New Jersey anti-poverty chari... film print of Michael Jackson,s "Thriller&qu...
(Date:7/3/2009)... Two companies and three individu...ence at an annual international competition design.... The 15,000-member SafetyXChange.org community r...une 30, 2009 at http://www.safetyxchange.org/saxc... organizations who dedicate their lives to keeping...
(Date:7/3/2009)... "This is an opportunity for...taking our Diabetic Free pills, you will experienc... diabetes: your blood sugar, cholesterol levels an...will be revitalized and your mind will finally be ...life of a diabetes patient." , ...
Breaking Medicine News(10 mins):Health News:A New Jersey Charity Seeks Serious Inquiries for Historic 35mm Film Print of Michael Jackson's "Thriller" Music Video 2Health News:A New Jersey Charity Seeks Serious Inquiries for Historic 35mm Film Print of Michael Jackson's "Thriller" Music Video 3Health News:A New Jersey Charity Seeks Serious Inquiries for Historic 35mm Film Print of Michael Jackson's "Thriller" Music Video 4Health News:A New Jersey Charity Seeks Serious Inquiries for Historic 35mm Film Print of Michael Jackson's "Thriller" Music Video 5Health News:Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 2Health News:Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 3Health News:Excellence in Workplace Safety Recognized as 2009 Saxcies Award Winners Named 4Health News:Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules 2Health News:Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules 3Health News:Patients Suffering from Diabetes Now Have the Option to Suffer No More with Diabetic Free All Natural Medical Herbal Extracts Capsules 4
...ter chip implanted near the eye’s retina is well o... blinded by eye diseases such as Retinitis Pigment...e benefitted by the new development.// The implan...y retinal neurons remain intact after they lose us...
...ng to researchers, people with receding lower jaws...reathing. Sleep apnoea is a condition which is cha...k of the throat during sleep, impeding the free fl... accompanied by snoring and the person actually st...
...ng to researchers, the risk of undergoing open hea...beyond seems to dropping, making the procedure saf.... Todd Rosengart, an associate professor of surger...rt surgery, if indicated, is safe and will improve...
...e aspirin for pains and to prevent heart attacks, ...immune system strong. A new study says aspirin and...a common// virus linked to potentially deadly infe...immune disorders. The presence of the microbe, ca...
Other Medicine News:Health News:Heart Surgery Is Getting Safer for the Old 2
(Date:6/29/2009)...ve Study Seeks to Assess RSV Burden in Outpatient ...mitment to Pediatric Research , , GAITHERSBUR...s to advance its commitment to pediatric research ...al prospective study designed to assess the burden...m infants 32-to-35 weeks gestational age (GA) in o...
(Date:6/29/2009)...AMPTON, England, June 29 Vantia Th...veloping novel, small molecule drugs,targeting la...ve results from,a Phase IIa clinical trial of its... The trial showed that oral VA106483 was successfu...iuretic effect in patients, as determined by,incr...
(Date:6/26/2009)..., Ill., June 26, and OSAKA, Japan, June 27, 2009 /...ed ("Takeda") today announced that Takeda Global R...wned United States (U.S.) subsidiary received on J... the U.S. Food and Drug Administration (FDA) regar...alogliptin, a selective dipeptidyl peptidase IV (D...
(Date:6/26/2009)...Opinion Recommends Approval of New Anti-TNF Therap...(TM) Autoinjector , , HORSHAM, Pa. and KENILWOR...or Ortho Biotech Inc. and Schering-Plough Corporat...tee for Medicinal Products for Human Use (CHMP) of...sitive opinion recommending the approval of SIMPON...
Breaking Medicine Technology:MedImmune Funds Study to Help Gain Insights Into Full Burden of RSV Disease Among Premature Infants 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 2Vantia Therapeutics' Lead Candidate VA106483 Demonstrates Positive Anti-diuretic Effect in Phase IIa Trial in Nocturia 3Takeda Receives FDA Complete Response Letter for Alogliptin, an Investigational Treatment for Type 2 Diabetes 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 4SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 5SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 6SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 7SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 8SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 9SIMPONI(TM) (golimumab) Receives Positive Opinion From CHMP for Once-Monthly Subcutaneous Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 10West to Host 2008 First Quarter Conference Call 17690 1West to Host 2008 First Quarter Conference Call 17690 2deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results 4856 1deCODE genetics Announces Webcast of Conference Call to Discuss First Quarter 2008 Financial Results 4856 2Number of HIV Positive State and Federal Inmates Continues to Decline 17685 1Number of HIV Positive State and Federal Inmates Continues to Decline 17685 2Number of HIV Positive State and Federal Inmates Continues to Decline 17685 3Pharma Industry Group Favors Obama as Next President 17681 1Pharma Industry Group Favors Obama as Next President 17681 2
....--(BUSINESS WIRE)--May 17, 2007 - Results,publish...cal cancer,vaccine, GARDASIL (Quadrivalent Human P...ccine) was 100 percent effective in,preventing hig...V,types 16 and 18, two types strongly associated w... observed in women who were not,infected with HPV ...
... 17, 2007 /PRNewswire-FirstCall/ -- DURECT,Corpora...as,provided its shareholders with an update on its...investigational drug for the,treatment of Alzheime... that they have observed positive outcome trends a...CT has not,independently verified the analysis per...
Other Medicine Technology:Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 2Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 3Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 4Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 5Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 6Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 7Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 8Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 9Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 10Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 11Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 12Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 13Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 14Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 15Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 16Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 17Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 18Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 19Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 20Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 21Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 22Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 23Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 24Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 25Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 26Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 27Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 28Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 29Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 30Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 31Data Published in The Lancet Show Gardasil was 100 Percent,Effective in Preventing High-Grade Vulvar and Vaginal Lesions,Caused by HPV Types 16 and 18 32DURECT Provides an Update to the Memryte Program Under Development,by Voyager Pharmaceutical Corp 2
Large deep curve.
3 mm electrode Inserts - monopolar foot control connection.
The ARK-760A is an Auto Refractor/Keratometer with both visual acuities and subjective refinement. Electronic elevation, automatic alignment, focusing, printing, high-speed measurement, unequalled ac
Sterile perfluorocarbon for intraocular Application.
Medicine Products: